We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Alternative Cancer Treatments May Be Based on Green Tea Components

By LabMedica International staff writers
Posted on 10 Feb 2015
A recent paper suggested that the green tea component epigallocatechin-3-gallate (EGCG) could be developed into an alternative treatment for oral cancer that would not have the severe side effects of current chemotherapeutic agents. More...


EGCG is the most abundant catechin in tea and is a potent antioxidant that may have therapeutic applications in the treatment of many disorders. It is found in green tea but not black tea.

Investigators at Pennsylvania State University (University Park, USA) previously reported that EGCG could induce oxidative stress in oral cancer cells but exerted antioxidant effects in normal cells. Now, in a follow-up study, they treated cultures of human oral squamous carcinoma cells (SCC-25, SCC-9), pre-malignant leukoplakia cells (MSK-Leuk1), and normal human gingival fibroblast cells (HGF-1) with various doses of EGCG.

They reported in the November 17, 2015, online issue of the journal Molecular Nutrition and Food Research that EGCG suppressed sirtuin 3 (silent mating type information regulation 2 homolog 3 or SIRT3) mRNA and protein expression, as well as SIRT3 activity in SCC-25 cells, whereas it increased SIRT3 activity in HGF-1 cells. SIRT3 is the third member of the mammalian sirtuin family, which exhibits NAD+-dependent deacetylase activity.

EGCG selectively decreased the nuclear localization of the estrogen-related receptor alpha (ERRalpha), the transcription factor regulating SIRT3 expression, in SCC-25 cells. This indicated that EGCG might regulate SIRT3 transcription in oral cancer cells via ERRalpha. EGCG also differentially modulated the mRNA expressions of SIRT3-associated downstream targets including glutathione peroxidase 1 and superoxide dismutase 2 in normal and oral cancer cells.

"EGCG plays an important role in mitochondrial function and in anti-oxidant response in lots of tissues in the body, so the idea that EGCG might selectively affect the activity of sirtuin 3 in cancer cells—to turn it off—and in normal cells—to turn it on—is probably applicable in multiple kinds of cancers," said senior author Dr. Joshua D. Lambert, associate professor of food science at Pennsylvania State University. "EGCG is doing something to damage the mitochondria and that mitochondrial damage sets up a cycle causing more damage and it spirals out, until the cell undergoes programmed cell death. It looks like EGCG causes the formation of reactive oxygen species in cancer cells, which damages the mitochondria and the mitochondria responds by making more reactive oxygen species."

"The problem with a lot of chemotherapy drugs - especially early chemotherapy drugs - is that they really just target rapidly dividing cells, so cancer divides rapidly, but so do cells in your hair follicles and cells in your intestines, so you have a lot of side effects," said Dr. Lambert. "But you do not see these sorts of side effects with green tea consumption."

Related Links:

Pennsylvania State University



New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Rapid Sepsis Test
SeptiCyte RAPID
New
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.